María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.
Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Recent Articles
The Middle Ages: Controversies in the Treatment of Adolescents and Young Adults With Leukemia
Over the past few decades, survival rates for pediatric patients with acute lymphocytic leukemia (ALL) have improved dramatically, with five-year survival rates now often...
Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...
People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...
Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis
Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...
My Fair MDs: Encouraging Doctors to Speak Plainly
“An Englishman's way of speaking absolutely classifies him.
The moment he talks he makes some other Englishman despise him.
One common language I'm afraid we'll never...
FDA Approves Powerful Synthetic Opioid
The U.S. Food and Drug Administration (FDA) has approved a new form of the synthetic opioid sufentanil for the management of acute pain in...
Current Issue
November 2018, Volume 4, Issue 13
This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.
